Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study

Diel, Ingo J.; Kurth, Andreas; Sittig, Hans-Bernd; Meden, Harald; Maasberg, Michael; Sandermann, Andreas; Bergner, Raoul

doi:10.1007/s00520-009-0749-5

Cited by 15 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, among patients who had no or mild pain at baseline, 57% to 66% reported progression to moderate or severe pain by study end; yet, among those who had no or low analgesic use at baseline, only 26% to 29% reported strong opioid use on study. This observation has been reported consistently in other studies 22‐24. Additional research can help to determine whether strong opioid use is low in these patients because of physician under‐treatment of pain, under‐reporting of pain by patients to physicians, patient or physician fear of opioid‐related side effects, or a combination of these factors.…”

Section: Discussionsupporting

confidence: 69%

Pain outcomes in patients with advanced breast cancer and bone metastases

Cleeland

Body

Stopeck

et al. 2012

Cancer

127

View full text Add to dashboard Cite

BACKGROUND:In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. METHODS: The prevention of pain, reduction in pain interference with daily life activities, and the proportion of patients requiring strong opioid analgesics were assessed in a randomized, double-blind, double-dummy phase 3 study comparing denosumab with ZA for preventing skeletal-related events in 2046 patients who had breast cancer and bone metastases. Patients completed the Brief Pain Inventory-Short Form at baseline and monthly thereafter. RESULTS: Fewer patients who received denosumab reported a clinically meaningful worsening of pain severity (!2-point increase) from baseline compared with patients who received ZA, and a trend was observed toward delayed time to pain worsening with denosumab versus ZA (denosumab, 8.5 months; ZA, 7.4 months; P ¼ .08). In patients who had no/mild pain at baseline, a 4-month delay in progression to moderate/severe pain was observed with denosumab compared with ZA (9.7 months vs 5.8 months; P ¼ .002). Denosumab delayed the time to increased pain interference by approximately 1 month compared with ZA (denosumab, 16.0 months; ZA, 14.9 months; P ¼ .09). The time to pain improvement (P ¼ .72) and the time to decreased pain interference (P ¼ .92) were similar between the groups. Fewer denosumab-treated patients reported increased analgesic use from no/low use at baseline to strong opioid use. CONCLU-SIONS: Denosumab demonstrated improved pain prevention and comparable pain palliation compared with ZA. In addition, fewer denosumab-treated patients shifted to strong opioid analgesic use. Cancer 2013;119:832-8.

show abstract

Section: Discussionsupporting

confidence: 69%

Pain outcomes in patients with advanced breast cancer and bone metastases

Cleeland

Body

Stopeck

et al. 2012

Cancer

127

View full text Add to dashboard Cite

show abstract

“…[100–3106–11118–20122129139144145153158164176180] Among the original articles, there were 12 qualitative studies[115116118–20122124126–8155169–71173] and 56 quantitative studies. [89–99104105112–4117121123125130–8140–3146–52154156157159–63165–8172174175177–9] There were eight randomized clinical trials,[94143150157161162167177] 12 non-randomized clinical trials,[8999113125137147149151163172175178] 11 cohort studies,[9597121123130131133154156165168] zero case-control studies, 10 cross-sectional studies[9396114…”

Section: Resultsmentioning

confidence: 99%

Reporting characteristics of cancer pain: A systematic review and quantitative analysis of research publications in palliative care journals

Kumar

2011

Indian J Palliat Care

View full text Add to dashboard Cite

Objective:A common disorder requiring symptom palliation in palliative and end-of-life care is cancer. Cancer pain is recognized as a global health burden. This paper sought to systematically examine the extent to which there is an adequate scientific research base on cancer pain and its reporting characteristics in the palliative care journal literature.Materials and Methods:Search conducted in MEDLINE and CINAHL sought to locate all studies published in 19 palliative/ hospice/ supportive/ end-of-life care journals from 2009 to 2010. The journals included were: American Journal of Hospice and Palliative Care, BMC Palliative Care, Current Opinion in Supportive and Palliative Care, End of Life Care Journal, European Journal of Palliative Care, Hospice Management Advisor, Indian Journal of Palliative Care, International Journal of Palliative Nursing, Internet Journal of Pain Symptom Control and Palliative Care, Journal of Pain and Palliative Care Pharmacotherapy, Journal of Palliative Care, Journal of Palliative Medicine, Journal of Social Work in End-of-life and Palliative Care, Journal of Supportive Oncology, Palliative Medicine, Palliative and Supportive Care, and Supportive Care in Cancer. Journal contents were searched to identify studies that included cancer pain in abstract.Results:During the years 2009 and 2010, of the selected 1,569 articles published in the journals reviewed, only 5.86% (92 articles) were on cancer pain.Conclusion:While researchers in the field of palliative care have studied cancer pain, the total percentage for studies is still a low 5.86%. To move the field of palliative care forward so that appropriate guidelines for cancer pain management can be developed, it is critical that more research be reported upon which to base cancer pain therapy in an evidence-based palliative care model.

show abstract

“…These findings indicate that a variety of bisphosphonates can be used during the course of a patient's disease. During postmarketingsurveillanceforupto24weeksofthe712patients reporting pain at baseline, 70% showed improvement after ibandronatetreatment(i.v.andoral)withameanoveralldecreaseinpainscoreof1.6(p<0.0001) [63].Meanpainscores were reduced in 205 patients previously treated with other bis phosphonates (-1.0; p < 0.0001) and in 59 patients with prioribandronatetreatment(-0.5;p=0.0108).Therewasno overall change in performance status in this study. A case series of 44 patients showed similar findings [64].…”

Section: Administration and Tolerability Of Ibandronatementioning

confidence: 88%

Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

Sittig¹

2012

Onkologie

Self Cite

View full text Add to dashboard Cite

Bone metastases are the most common cause of pain in patients with advanced cancer, and are associated with progressive skeletal destruction, spinal problems, and hypercalcaemia. Radiotherapy, analgesia, and surgery are the accepted treatment options for chronic malignant bone pain, with a stepped approach being generally recommended. In the past decade, the bisphosphonates, which reduce bone turnover, increase bone mass, and decrease the risk of fracture, have become established as an effective treatment in patients with cancer metastasising to bone. The nitrogencontaining bisphosphonate, ibandronate, has been shown to reduce the risk of skeletal events after oral or intravenous administration in controlled clinical trials in various malignancies, and to confer significant palliation of bone pain and improvements in health-related quality of life in patients with metastatic breast cancer, in particular. Tolerability of this agent has been good, with very low frequencies of acute-phase reactions and osteonecrosis of the jaw, and no evidence of acute nephrotoxicity.

show abstract

Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study

Abstract: Data from this non-interventional study confirm the analgesic efficacy and safety profile of IV and oral ibandronate under real-life conditions.

Cited by 15 publications

References 20 publications

Pain outcomes in patients with advanced breast cancer and bone metastases

Pain outcomes in patients with advanced breast cancer and bone metastases

Reporting characteristics of cancer pain: A systematic review and quantitative analysis of research publications in palliative care journals

Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

Contact Info

Product

Resources

About